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Antisense oligonucleotides against collagen-binding stress
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Antisense oligonucleotides against collagen-binding stress pro-
tein HSP47 suppress peritoneal fibrosis in rats.
Background. Peritoneal fibrosis is a serious complication in
patients on continuous ambulatory peritoneal dialysis (CAPD),
but the molecular mechanism of this process remains unclear.
Heat shock protein 47 (HSP47), a collagen-specific molecular
chaperone, is essential for biosynthesis and secretion of colla-
gen molecules, and is expressed in the tissue of human perito-
neal fibrosis. In the present study, we examined the effect of
HSP47 antisense oligonucleotides (ODNs) on the development
of experimental peritoneal fibrosis induced by daily intraperito-
neal injections of chlorhexidine gluconate (CG).
Methods. HSP47 antisense or sense ODNs were injected
simultaneously with CG from day 14, after injections of CG
alone. Peritoneal tissue was dissected out 28 days after CG
injection. The expression patterns of HSP47, type I and type
III collagen, -smooth muscle actin (-SMA), as a marker of
myofibroblasts, ED-1 (as a marker of macrophages), and factor
VIII were examined by immunohistochemistry.
Results. In rats treated with CG alone, the submesothelial
collagenous compact zone was thickened, where the expression
levels of HSP47, type I and type III collagen and -SMA were
increased. Marked macrophage infiltration was also noted and
the number of vessels positively stained for factor VIII in-
creased in the CG-treated group. Treatment with antisense
ODNs, but not sense ODNs, abrogated CG-induced changes
in the expression of HSP47, type I and III collagen, -SMA,
and the number of infiltrating macrophages and vessels.
Conclusion. Our results indicate the involvement of HSP47
in the progression of peritoneal fibrosis and that inhibition of
HSP47 expression might merit further clinical investigation for
the treatment of peritoneal fibrosis in CAPD patients.
Continuous ambulatory peritoneal dialysis (CAPD)
causes morphologic [1] and functional changes in the
peritoneum. Characteristic pathologic findings in the
peritoneum of patients with long-term CAPD therapy
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include marked peritoneal fibrosis and massive accumu-
lation of collagen [2, 3]. In particular, some patients
develop encapsulating peritoneal sclerosis (EPS) associ-
ated with high mortality, which is one of the most serious
complications [4]. The mechanism of peritoneal fibrosis
in CAPD patients remains poorly understood and no
effective therapy is available at present. Although there
is no experimental model for peritoneal fibrosis similar
to that of patients on CAPD, Suga et al [5] and Ishii
et al [6] developed experimental models for peritoneal
fibrosis in rats and EPS in mice, respectively, by perito-
neal injection of chlorhexidine gluconate (CG). Many
pathologic findings in the peritoneum from CAPD pa-
tients, including increased expression of type III collagen,
heat shock protein 47 (HSP47), -smooth muscle actin
(-SMA), and macrophage infiltration, are also observed
in the peritoneum of animals injected with CG [7, 8].
HSP47, a collagen-specific molecular chaperone, is es-
sential for the biosynthesis and secretion of procollagen
molecules [9], and implicated in diseases associated with
hepatic [10] and pulmonary fibrosis [11]. Recent studies
reported the presence of high expression levels of HSP47
in various kidney diseases, such as human transplanted
kidney with fibrosis [12], renal interstitial fibrosis induced
by unilateral ureteral obstruction [13], experimental mes-
angial proliferative glomerulonephritis [14], age-related
nephropathy [15], and gentamicin-induced renal injury [16].
Furthermore, we previously demonstrated the expres-
sion of HSP47 in the fibrotic peritoneal tissue from pa-
tients on CAPD, and its level correlated well with that of
type III collagen [7]. Other studies showed that antisense
oligonucleotides (ODNs) of HSP47 inhibited collagen
synthesis in 3T6 cells [17] and in experimental prolifera-
tive glomerulonephritis induced by anti-thy-1 antibody
[18]. These findings suggest the important role of HSP47
in collagen synthesis in various fibrotic disorders.
Mishima et al [8] recently demonstrated that HSP47
expression significantly correlated with accumulation of
collagen type I and III in CG-induced peritoneal fibrosis.
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In the present study, we investigated the importance of
HSP47 in peritoneal fibrosis by examining whether ODNs
against HSP47 inhibit the development of CG-induced
peritoneal fibrosis. To our knowledge, our study is the
first to report that inhibition of HSP47 expression results
in suppression of collagen accumulation in an experi-
mental peritoneal fibrosis model. In addition, macro-
phage infiltration and angiogenesis, which were other
characteristic findings in peritoneal fibrosis, were also
inhibited by antisense ODNs.
METHODS
HSP47 antisense ODNs
Antisense phosphorothioate ODNs against the first five
codons of HSP47 that straddle the predicted translation
initiation site of the mouse HSP47 mRNA were used.
The antisense and sense ODNs were purchased from
Beck’s (Tokyo, Japan).
Animals
Male Wistar rats weighing 250 to 300 g were used in
this study. They were housed in standard rodent cages, at
constant ambient temperature (22  1C) and humidity
(85%), with 10 hours of lights each day. Drinking water
and pelleted rodent food were provided ad libitum. The
experimental protocol was approved by the Ethics Re-
view Committee for Animal Experimentation of Naga-
saki University School of Medicine.
Experimental protocol
In control experiments, we injected sense or antisense
ODNs with 15% ethanol dissolved in 2 mL saline. Perito-
neal fibrosis was induced as described previously by Suga
et al [4]. Briefly, under ether anesthesia, rats received a
daily intraperitoneal injection of 0.1% CG in 15% etha-
nol dissolved in 2 mL of saline over a period of 28 days
(CG group, N  5). In another group of rats, the same
CG preparation was injected intraperitoneally at a simi-
lar dose but for only 14 days, followed by injection of
antisense or sense ODNs (500 g/kg) with CG for an-
other 14 days (antisense ODNs–treated group, N  5;
sense ODNs–treated group, N 5). Rats were sacrificed
at 14, 17, 21, or 28 days after the first CG injection and
peritoneal tissues were dissected out carefully. Control
rats were also injected with 15% ethanol dissolved in
2 mL of saline for 28 days (E-saline group, N  5).
To avoid direct damage to the peritoneum caused by
repeated injections, injections were made at the lower
part of the peritoneum while the upper portion of the
parietal peritoneum was used for histopathologic exami-
nation. The harvested tissues were fixed with 4% para-
formaldehyde immediately after sampling and embed-
ded in paraffin. For histopathologic examination,
paraffin-embedded tissue sections (4 m thick) were
stained with periodic acid Schiff (PAS). We measured
the thickness of the submesothelial compact zone above
the muscles of the abdominal wall at 5 points in each
group and the thickness was presented as mean  SD.
Examination of ODNs transfer into peritoneal cavity
Using fluorescein isothiocyanate (FITC)–labeled anti-
sense ODNs against HSP47, we evaluated the uptake of
antisense ODNs into the peritoneal tissue. FITC-labeled
antisense ODNs (Beck’s) were injected into the perito-
neal cavity of rats treated with CG for 14 days and of
untreated control rats. Peritoneal tissues were dissected
out from both groups and embedded in O.C.T. compound
(Miles, Inc., Elkhart, IN, USA). The peritoneal speci-
mens were cut to a thickness of 4 m. The tissue sections
were washed in phosphate-buffered saline (PBS) and
examined by fluorescence microscopy (Zeiss, Oberkochen,
Germany).
Immunohistochemistry
Paraffin-embedded tissue sections (4 m thick) were
stained immunohistochemically using an indirect method.
Deparaffinized tissue sections were incubated for 30 min-
utes with a blocking buffer containing 10% normal goat
serum and 10% fetal calf serum (FCS) in PBS. The sections
were then reacted for 1 hour with the following primary
antibodies, which were diluted in the same incubation
buffer: a monoclonal antibody against mouse HSP47,
which also reacts with rat HSP47 diluted 1/100 (Stress-
Gen, Victoria, British Columbia, Canada); -smooth
muscle actin (-SMA) diluted 1/500 and used as a marker
for myofibroblasts (Dako, Glostrup, Denmark); ED-1
diluted 1/100 and used as a marker for macrophages/
monocytes (Serotec, Oxford, UK); a polyclonal antibody
against factor VIII diluted 1/200 and used as a marker
for blood vessels (von Willebrand factor, A0082, Dako,
Glostrup, Denmark); rat type I collagen diluted 1/75
(Chemicon International, Inc., Temecula, CA, USA); rat
type III collagen diluted 1/50 (Chemicon International,
Inc.); and rat type IV collagen diluted 1/75 (Chemicon
International, Inc.). After reacting with the primary anti-
body, the sections were reacted for 30 minutes with the
following secondary antibodies diluted in the same incu-
bation buffer: horseradish peroxidase (HRP)–conjugated
rabbit anti-mouse antibody diluted 1/100 (P260, Dako)
and HRP-conjugated swine anti-rabbit antibody (P399,
Dako) for monoclonal antibodies, and with HRP-conju-
gated swine anti-rabbit antibody diluted 1/50 (P399,
Dako) and peroxidase anti-peroxidase antibody diluted
1/50 (Z0113, Dako) for polyclonal antibodies. Positive
reaction with the antibodies was characterized by color
development following reaction with H2O2 and 3-3 diami-
nobenzidine tetrahydrochloride. Finally, the sections
were counterstained with methyl green and mounted.
Peritoneal tissues were also immunohistochemically
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stained for transforming growth factor-beta 1 (TGF-1)
and vascular endothelial growth factor (VEGF) using a
polyclonal antibody against TGF-1 diluted 1/100 (sc-
146; Santa Cruz Biotechnology, Santa Cruz, CA, USA)
and a polyclonal antibody against VEGF diluted 1/100
(sc-507; Santa Cruz Biotechnology), respectively, fol-
lowed by avidin-biotin complex kit (Vectastain Elite
ABC Kit; Vector Laboratories, Burlingame, CA, USA)
according to the protocol provided by the manufacturer.
Negative control studies were performed by using ir-
relevant immunoglobulins (Ig) of subclasses similar to
those of the primary antibodies, such as nonspecific
mouse IgG1 (X931, Dako), IgG2 (X943, Dako), and
rabbit IgG (X903, Dako), instead of the primary antibod-
ies, which showed no positive cells (data not shown).
Double immunohistochemical staining
To identify the types of cells positive for FITC-labeled
antisense ODNs of HSP47, double immunostaining for
-SMA/FITC was performed using the method described
previously by Shioshita et al [7], with some modification.
After staining for -SMA using the protocol described
above, the sections were washed in PBS to stop the color
reaction. They were then incubated for 90 minutes at
room temperature with a blocking solution and reacted
with a polyclonal antibody against FITC [peroxidase-
conjugated rabbit anti-FITC (P0404, Dako)], followed
by incubation with HRP-conjugated antibodies as men-
tioned above. A second chromogen, True Blue (71-00-
64; KPL, Gaithersburg, MD, USA), was then applied,
resulting in the staining of positive cells in blue. The
tissue sections were not counterstained with methyl green,
since such counterstaining may interfere with the color
from the chromogen.
To examine whether antisense ODNs directly affected
cells that expressed HSP47, double staining for FITC
and HSP47 was performed as described above. Further-
more, to examine the contribution of ED-1–positive cells
to TGF- expression in the submesothelial compact
zone, we performed double immunostaining for ED-1
and TGF- in the same sections.
In situ hybridization
Non-radioactive in situ hybridization was performed
according to a modified technique originally developed
in our laboratory [19]. Sense and antisense ODNs for
rat HSP47 mRNA corresponded to base number 335-
373 of mouse HSP47 cDNA. The probe for rat monocyte
chemoattractant protein-1 (MCP-1) mRNA corresponded
to sequence numbers 83-121 of cDNA. The selected se-
quences are significantly different from other known se-
quences deposited in the latest release of gene bank data
(GenBank, Release 123, 2001). Briefly, the peritoneal
specimens were fixed with 4% paraformaldehyde in PBS.
The sections were deproteinized using HCl and protein-
ase K. After prehybridization, the sections were hybrid-
ized with digoxigenin (DIG)-labeled oligonucleotide probe
in prehybridization buffer. After washing with 0.075%
BRIJ (430 AG-6; Sigma Chemical Co., St. Louis, MO,
USA) in 2  standard sodium citrate (SSC) and 0.5 
SSC, immunohistochemistry was performed to visualize
DIG-labeled probe using mouse monoclonal anti-DIG
antibody, HRP-conjugated rabbit anti-mouse antibody
(P260, Dako), and HRP-conjugated swine anti-rabbit
antibody (P399, Dako). Color was developed by reaction
with H2O2 and diaminobenzidine. Finally, the sections
were counterstained with methyl green and mounted.
To evaluate the specificity of the mRNA signal, we per-
formed three control experiments, including pretreat-
ment of RNase, a study with a sense probe, and a compet-
itive study, as described previously [19]. We also checked
for no cross-reaction of mouse monoclonal anti-DIG
antibody, HRP-conjugated rabbit anti-mouse antibody,
and HRP-conjugated swine anti-rabbit antibody (data
not shown).
Furthermore, to examine the intrinsic changes induced
by injection of antisense ODNs, we analyzed the expres-
sion of 28S rRNA, which is ubiquitously expressed in
living cells [20], in peritoneal tissue samples obtained
from rats treated with antisense ODNs, sense ODNs, or
without any ODNs, by using in situ hybridization as
described previously [21].
Data processing and statistical analysis
For semiquantitative estimation of the intensity of ex-
pression of each protein, image analysis of the stained
sections was performed using Olympus Image Analyzer
(Olympus, Tokyo, Japan) system as described previously
[7]. In brief, the image was transformed into a matrix of
1280  1000 pixels, and the voltage signal at each pixel
was converted to 1 to 256 intensity gray levels in propor-
tion to the colorimetric staining. By summing the values
of pixels in five sections, each measuring 0.14 mm2, from
different fields of the submesothelial region at 200
magnification, we could determine the signal density for
HSP47, type I and III collagen, and -SMA. Then, we
compared the density of these markers per 0.14 mm2
among the four groups. The number of ED-1–positive
cells and blood vessels positive for factor VIII were also
counted in the same fields at 200 magnification.
Data are expressed as mean SD. Differences among
groups were examined for statistical significance using
repeated-measures analysis of variance (ANOVA) (Bon-
ferroni/Dunn test). A P value less than 0.05 denoted the
presence of statistically significant differences.
RESULTS
Transfer of ODNs into the peritoneal cavity
To examine the toxicity of antisense ODNs, we in-
jected antisense ODNs alone into the peritoneal cavity
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Fig. 1. Uptake of fluorescein isothiocyanate (FITC)-labeled phosphor-
othioated oligonucleotides (ODNs) in the peritoneum and double stain-
ing for FITC (in blue)/-smooth muscle actin (-SMA) (in brown) in
the same sections. (A ) Representative fluorescence photomicrographs
of ODNs peritoneal uptake 30 minutes after intraperitoneal injection
of FITC-labeled ODNs. (B ) Cells positive for FITC are spindle shaped
(see inset). (C ) Note that -SMA–positive cells are also positive for
FITC. (D ) -SMA–positive cell are not positive for FITC. (A) 400
magnification; (B, C and D), 800 magnification.
for 28 days, but no morphologic changes were found
(data not shown). The toxicity of antisense and sense
ODNs was further checked using an in vitro system. Rat
mesothelial cells were incubated with 10% FCS with/
without 75 g/mL of antisense and sense ODNs (same
concentrations of antisense ODNs were applied in subse-
quent in vivo experiments). The supernatants were as-
sessed by measuring lactate dehydrogenase (LDH) lev-
els, as described previously [22]. There was no significant
difference in LDH levels in supernatants treated with
antisense or sense ODNs (data not shown). In situ hy-
bridization study for 28S rRNA also showed no differ-
ence in the expression pattern of 28S rRNA in peritoneal
tissues obtained from rats treated with antisense ODNs,
sense ODNs, or no ODNs. These data suggested that
antisense ODNs were not toxic, as they did not induce
any intrinsic changes.
To confirm the uptake of antisense ODNs into the
peritoneal tissue, FITC-labeled antisense ODNs were
injected into the peritoneal cavity, followed by examina-
tion of the peritoneum under fluorescence microscopy.
In normal rat peritoneum, very few FITC-positive cells
were observed in the peritoneum (data not shown), indi-
cating that FITC did not bind nonspecifically to any cells
in the peritoneum. As shown in Figure 1, many spindle
shaped cells were positive for FITC in the submesothelial
compact zone. Counting of the number of FITC-positive
Fig. 3. Immunohistochemistry for heat shock protein 47 (HSP47). In
the control group, HSP47 is weakly but significantly expressed in meso-
thelial cells (see inset, arrowheads) (A ). In the chlorhexidine gluconate
(CG) group, the number of cells positive for HSP47 is increased in
thickened submesothelial compact zone (see inset, spindle-shaped cells
are positive for HSP47; arrowheads) (B ). Antisense oligonucleotides
(ODNs) decreased the expression of HSP47 (C ) compared with that
in sense ODNs group (D ). (A to D, 400 magnification; A and B
insets, 600 magnification).
cells and total cells in submesothelial compact zone un-
der immunofluorescence and light microscopy, respec-
tively, showed that 42.3  5.6% of cells in the thickened
submesothelial area were positive for FITC-labeled anti-
sense ODNs. Double staining for FITC and -SMA was
performed to determine the type of cells positive for
FITC-labeled ODNs (Fig. 1). The staining revealed that
59.6  1.3% of FITC-expressing cells was stained for
-SMA. Furthermore, the proportion of FITC-positive
cells among -SMA–positive cells in the submesothelial
compact zone was 52.3  2.1%. Double staining for
FITC and HSP47 was performed to recognize FITC-
labeled antisense ODNs that directly affected HSP47-
expressing cells. Quantitative analysis indicated that 49.3
3.2% of the HSP47-positive cells also expressed FITC
in the submesothelial compact zone.
Figure 2 shows representative PAS-stained peritoneal
tissue samples. In rats of the E-saline group, the PAS-
stained peritoneum consisted of a monolayer of mesothelial
cells that covered the surface without any thickening of
the peritoneum (Fig. 2A). In rats injected with sense or
antisense ODNs with 15% ethanol dissolved in 2 mL saline,
the results were similar to those of the E-saline group
(data not shown). At days 14 and 28, the peritoneal tissue
in the CG group was markedly thickened and showed
marked proliferation of collagen fibers (Fig. 2 B and
C). On the other hand, treatment with HSP47 antisense
ODNs (Fig. 2D), but not with the sense ODNs (Fig.
2E), resulted in a decrease in CG-induced peritoneal
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Fig. 2. Periodic acid Schiff (PAS) staining of peritoneal tissues. Control
rats injected with ethanol and saline at 28 days (A ). Note the monolayer
of mesothelial cells covering the entire surface of the peritoneum. In
chlorhexidine gluconate (CG) group, significant thickening of the peri-
toneum was markedly noted in the compact zone at 14 days (B ). In the
CG group at 28 days, note the marked thickening of the submesothelial
compact zone (C ), while treatment with heat shock protein 47 (HSP47)
antisense (D ), not sense oligonucleotides (ODNs) (E ), prevented the
progression of peritoneal thickening. Bars indicate the area of compact
zone. Magnification, 200.
thickening. Reduction of peritoneal thickness was seen
in antisense-treated rats from day 21 and significant re-
duction was observed at day 28. These results were also
confirmed upon measurement of the thickness of subme-
sothelial compact zone with image analysis software
(control, 6.6 1.6; CG group, 265 31; antisense ODNs,
160  36; sense ODNs, 274  35 m; P  0.01 between
CG and control, and between CG and antisense ODNs).
Expression of HSP47
Figure 3 shows the results of immunohistochemistry
for HSP47. In the control group, HSP47 was weakly but
significantly expressed in mesothelial cells (Fig. 3A). In
CG- and sense ODNs–treated groups, the number of
HSP47-positive cells was higher in the thickened subme-
sothelial compact zone (Fig. 3 B and D), while in anti-
sense ODNs–treated group, the relative number of
HSP47-positive cells was lower (Fig. 3C). Morphologi-
cally, most HSP47-positive cells were mesothelial cells
located on the surface of the peritoneum and spindle-
shaped fibroblasts located in the submesothelial compact
Fig. 4. Heat shock protein 47 (HSP47) expression in the peritoneum
of chlorhexidine gluconate (CG)-injected rats, control rats, and rats
treated with antisense and sense oligonucleotides (ODNs) for HSP47.
Data are mean  SD of the sum of pixel values of HSP47 expression
in the peritoneum. HSP47 expression was not altered in CG/sense
ODNs–treated group, and the degree of HSP47 expression was similar
to that in CG group. *P  0.01.
Fig. 5. In situ hybridization for heat shock protein 47 (HSP47) mRNA.
In chlorhexidine gluconate (CG) group, note the strong expression of
HSP47mRNA in the thickened submesothelial compact zone (A ), while
such expression is decreased in antisense group (B ). 400 magnifica-
tion.
zone (Fig. 3 A and B, arrowheads). Semiquantitative
analysis showed that the expression of HSP47 was sig-
nificantly higher in the CG group than in the control,
while treatment with HSP47 antisense ODNs signifi-
cantly reduced HSP47 expression (Fig. 4). There was no
difference in HSP47 expression between CG and sense
ODNs–treated group.
In situ hybridization for HSP47 mRNA
We also examined whether treatment with antisense
ODNs inhibited the expression of HSP47 mRNA. In the
CG group, the expression of HSP47 mRNA was evident
in the thickened submesothelial compact zone (Fig. 5A),
while it was markedly inhibited by treatment with anti-
sense ODNs of HSP47 (Fig. 5B). Sense ODNs did not
alter the enhanced expression of HSP47 mRNA. In the
control group, only a weak expression of HSP47 mRNA
was noted in some mesothelial cells (data not shown).
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Fig. 6. Immunohistochemistry for types III (A to D ) and I collagen
(E and F ). Peritoneal tissue injected with ethanol and saline (control
group) (A). Note the weak expression of type III collagen in the subme-
sothelial area at 28 days. In chlorhexidine gluconate (CG) group, the
expression levels of type III collagen are markedly increased in the
submesothelial compact zone at 14 (B) and 28 days (C). In antisense
group at 28 days, the expression of type III collagen is clearly decreased
(D) compared with that in CG group (C). Type I collagen is strongly
expressed in the submesothelial compact zone in CG group (E), but it
is clearly decreased in antisense-treated group at 28 days (F). Bars
indicate the area of compact zone. Magnification, 200.
Expression of types I, III, and IV collagen
Figure 6 shows the results of immunohistochemistry
for type III collagen. The expression of type III collagen
was very weak in the control group (Fig. 6A). In the CG
group, the expression of type III collagen was evident
in the thickened submesothelial compact zone at days
14 and 28 (Fig. 6 B and C), while this expression was
clearly decreased in the antisense ODNs–treated group
(Fig. 6D). No difference in type III collagen expression
was observed between the CG and sense ODNs–treated
groups. As for type I collagen, the expression pattern
was similar to that of type III collagen (Fig. 6 E and F),
while the expression of type IV collagen was absent in
the submesothelial compact zone in this experiment
(data not shown). Semiquantitative analysis showed that
the expression of type I and III collagen was higher
in the CG group, but significantly lower in antisense
ODNs–treated group compared with that in CG and
sense ODNs–treated groups (Fig. 7 A and B).
Fig. 7. Expression of (A ) type III and (B ) type I collagen in the
peritoneum of chlorhexidine gluconate (CG)-injected rats, control rats,
and rats treated with antisense or sense oligonucleotides (ODNs) for
heat shock protein 47 (HSP47). Data are mean  SD of the sum of
pixel values of types III and I collagen expression in the peritoneum.
*P  0.01.
Expression of -SMA, ED-1, and MCP-1 mRNAs
To identify the type of cells abundantly present in the
submesothelial area of the peritoneum of the CG group,
we performed immunohistochemistry for -SMA, a
marker for activated fibroblasts (myofibroblasts) and
ED-1, a marker for macrophages. In the control group,
staining for -SMA was present only in the blood vessel
wall and no positive cells for ED-1 were detected in the
peritoneum (data not shown). In the CG group, -SMA
was highly expressed in the markedly thickened compact
zone (Fig. 8A), while the expression was markedly de-
creased in the antisense ODNs–treated group (Fig. 8B).
ED-1–positive cells were present in the thickened com-
pact zone in CG group (Fig. 8C), while their number
was reduced in the antisense ODNs–treated group (Fig.
8D). Table 1 summarizes the results of quantitative anal-
ysis of the number of -SMA–positive and ED-1–positive
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Fig. 8. Immunohistochemistry for (A and B ) -smooth muscle actin
(-SMA), (C and D ) ED-1, and (E and F ) in situ hybridization for
monocyte chemoattractant protein-1 (MCP-1) mRNA. In chlorhexidine
gluconate (CG) group, note the strong expression of -SMA in the
markedly thickened submesothelial compact zone (A), while such ex-
pression is decreased in antisense group (B). (C) In CG group, ED-
1–positive cells are present in thickened submesothelial compact zone.
(D) The number of ED-1–positive cells is reduced in antisense ODNs
group. In CG group, the expression of MCP-1 mRNA is evident in the
thickened submesothelial compact zone (E), while it is inhibited by
antisense treatment (F). Magnification, 400.
cells in the peritoneum of each group. The analysis
showed increased expression of -SMA and ED-1 in the
CG group and sense ODNs–treated rats relative to the
control and antisense ODNs–treated rats.
To determine the mechanism of the reduced number
of infiltrating macrophages in rats treated with antisense
ODNs of HSP47, we examined the expression of MCP-1
mRNA, which causes strong chemotaxis of macrophages.
In the CG group, the expression of MCP-1 mRNA was
evident in the thickened submesothelial compact zone
(Fig. 8E), where macrophages were markedly infiltrated,
while it was inhibited by antisense treatment (Fig. 8F).
Expression of factor VIII (von Willebrand factor)
Previous studies suggested that the number of blood
vessels increased in peritoneal sclerosis and that neovas-
cularization was involved in the development of perito-
neal fibrosis [23]. We also examined the effect of anti-
sense ODNs treatment on neovascularization in our
model. Many vessels were observed in the CG group
(Fig. 9A), while their number was decreased in antisense
ODNs–treated rats (Fig. 9B). Table 1 shows the number
of factor VIII–positive vessels in the peritoneum of each
group. The number of vessels stained for factor VIII was
significantly higher in the CG group than in the control
group. Treatment with antisense, but not sense of HSP47,
significantly reduced the number of vessels positive for
factor VIII compared with that in the CG group.
Expression of TGF- and VEGF
We examined the expression of TGF- and VEGF by
immunohistochemistry. The numbers of TGF-–positive
cells were increased in the thickened peritoneum in the
CG group (Fig. 10A), but markedly reduced in antisense-
treated group (Fig. 10B). We also examined the types
of cells that expressed TGF- in the thickened submeso-
thelial area under a higher magnification. Expression of
TGF- was identified mainly on fibroblasts, although it
was also detected on mononuclear cells, spindle-shaped
fibroblasts, and some mesothelial cells. Double staining
for TGF- and ED-1 confirmed that some ED-1–positive
cells were also positive for TGF-, indicating that some
macrophages express TGF- (data not shown). Finally,
the distribution of VEGF expression was similar to that
of TGF-.
DISCUSSION
In the present study, we confirmed the high expression
level of HSP47 during the progression of peritoneal fi-
brosis induced by intraperitoneal CG injection. Adminis-
tration of HSP47 antisense ODNs markedly reduced the
expression of HSP47 and prevented the progression of
peritoneal fibrosis in the rat model. Antisense treatment
commenced 2 weeks after injection of CG, when perito-
neal fibrosis had already begun, indicating the inhibitory
effect of HSP47 antisense ODNs on collagen synthesis
under the condition of enhanced collagen accumulation.
These findings suggest that the use of HSP47 antisense
ODNs could be potentially useful for suppressing the
progression of peritoneal fibrosis.
Although the pathogenesis of peritoneal sclerosis in
CAPD patients is still unclear, many factors are consid-
ered to be involved in the development of peritoneal
fibrosis. These include endotoxin [1, 24], acetate dialy-
sate [1, 2, 24], the use of antiseptics [24, 25], advanced
glycation end products [26], and carbonyl modifications
of peritoneal tissue [27]. In the present study, we used
a rat experimental model of peritoneal fibrosis induced
by CG. Whether this model is relevant to the peritoneal
sclerosis and encapsulating peritoneal sclerosis seen in
CAPD patients remains to be determined. However, it
can be assumed that certain common pathways exist
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Table 1. Results of immunohistochemistry for -SMA, ED-1, and factor VIII
Control CG Antisense ODNs Sense ODNs
Expression of -SMA 214.5111.5 17141023a 356176b 1208289a
ED-1–positive cells 2.11.4 73.821.7a 48.77.6a,b 82.822.9a
Number of vessels 1.91.6 67.418.8a 33.18.7a,b 74.322.6a
Abbreviations are: -SMA, -smooth muscle actin, CG, chlorhexidine gluconate; ODN, oligonucleotide; HSP47, heat shock protein 47.
Image analysis determined the signal density for -SMA by summation of the values of pixels in five fields in the submesothelial region (magnification 200).
The numbers of ED-1–positive cells and factor VIII–positive vessels were determined in five fields selected at random in the submesothelial region (magnification
200). Data are meanSD.
aP  0.01 vs. control; bP  0.01 vs. CG and HSP47 sense ODNs
Fig. 9. Immunohistochemistry for factor VIII. Note the presence of
numerous vessels positively stained for factor VIII in chlorhexidine gluco-
nate (CG) group (A), while fewer vessels are stained for factor VIII in
antisense oligonucleotides (ODNs) group (B). Magnification, 400.
during the development of peritoneal fibrosis between
our model and the CAPD patients. In fact, following
injection of CG as a nonspecific chemical to induce peri-
toneal fibrosis, many pathologic findings in the perito-
neum of CAPD patients (e.g., increased expression of
collagen type III, HSP47, -SMA, and macrophage infil-
tration) [7], were also observed in our model. Although
this model does not completely mimic human disease,
further studies are necessary to confirm the inhibitory
effects of HSP47 antisense ODNs on the progression of
peritoneal fibrosis in another model of human peritoneal
fibrosis. Furthermore, in addition to studying the mor-
phologic changes induced by HSP47 antisense ODNs, it
is also important to examine any functional changes in
the peritoneum induced by such treatment.
There are two possible mechanisms for the inhibitory
effects of antisense ODNs in the present study: (1) Inhi-
bition of translation. The sites of action of antisense
ODNs used in the present study are the first five codons
of HSP47 mRNA, which are the translation-initiation
site. The binding of antisense ODNs to this site may
inhibit the translation and subsequently reduce the ex-
pression of HSP47 protein, as shown in the present study;
and (2) degradation of mRNA by RNase. The binding
of antisense ODNs to mRNA allows RNase H, the sub-
strate of which are RNA/DNA duplex hybrids, to cleave
the mRNA of the hybrids [28]. In fact, we showed that
the expression of HSP47 mRNA in the peritoneum was
markedly reduced by antisense ODNs in our model.
Thus, antisense ODNs can potentially inhibit the expres-
sion of HSP47 mRNA and protein in the cells of the
Fig. 10. Immunohistochemistry for transforming growth factor-beta
(TGF-). In chlorhexidine gluconate (CG) group, the number of TGF-
–positive cells is markedly increased in the submesothelial compact
zone. Spindle-shaped cells (left inset panel) and round cells (right inset
panel) are positive for TGF- (A ), while their number is reduced in
antisense oligonucleotides (ODNs)–treated group (B ). Magnification,
A and B, 400; inset magnification, 800.
submesothelial compact zone. Examination of the type
of cells positive for antisense ODNs showed that 59.6%
of the FTIC-positive cells were -SMA–positive myofi-
broblasts. Since myofibroblasts are considered to be the
main site of production of collagen in peritoneal fibrosis
and HSP47 is a collagen-specific chaperone, a rather
good uptake efficacy of antisense ODNs by peritoneal
injection inhibited the expression of collagen and pre-
vented the progression of peritoneal fibrosis in the pres-
ent study.
We have previously shown a biphasic response of mac-
rophages in CG-induced peritoneal fibrosis [8], an initial
increase in the number of macrophages followed by a
fall in their number in advanced stages of fibrosis, similar
to the pattern seen in human biopsy specimens of perito-
neal sclerosis [7]. In this regard, Williams et al [3] demon-
strated in human biopsy specimens a lack of significant
infiltration of macrophages in samples collected from
CAPD patients. Differences in the pathologic stage of
peritoneal fibrosis may explain the discrepancies between
the studies. In the present study, treatment of rats with
antisense ODNs resulted in a reduction of the number
of infiltrating macrophages concurrent with inhibition of
progression of peritoneal fibrosis. Although the underly-
ing mechanism of antisense ODNs–induced reduction of
infiltrating macrophages in our model is not clear, our
in situ hybridization study showed a decrease in MCP-1
mRNA expression with reduction of collagen in the peri-
toneum of rats treated with antisense ODNs against
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HSP47. This is consistent with the results of previous
in vitro studies, which showed that collagen stimulated
MCP-1 expression in hepatic stellate and endometrial
cells [29, 30]. We can therefore speculate that HSP47
antisense ODNs can indirectly influence MCP-1 expres-
sion in the peritoneum by mediating collagen accumula-
tion and subsequent reduction of the number of infiltrat-
ing macrophages. Recent studies provided evidences for
the role of MCP-1 on the progression of tubulointerstitial
fibrosis in the kidney through macrophage recruitment
and activation [31, 32]. These studies emphasize the im-
portance of inflammation in the progression of fibrosis.
Although the relationship between inflammatory process
and development of (encapsulating) peritoneal sclerosis
in human remains unclear at present, further studies are
necessary to clarify the relationship between inflamma-
tion and peritoneal fibrosis. If inflammation drives the
fibrotic process under long-term peritoneal dialysis ther-
apy, measurements of pro-inflammatory cytokines in the
effluent could serve as a marker for the progression of
human peritoneal sclerosis. Further studies are needed
to determine the role of inflammatory cells, such as T
cells and B cells, in this process.
Various vessel-related abnormalities have been re-
ported in peritoneal fibrosis [33, 34]. The results of these
studies suggested the involvement of vascular abnormali-
ties during peritoneal fibrosis. In the present study,
HSP47 antisense ODNs reduced the number of vessels
and decreased the peritoneal thickness; however, the rela-
tionship between peritoneal fibrosis and angiogenesis re-
mains poorly understood. In this regard, previous in vitro
studies showed that culture of endothelial cells with col-
lagen type I and III enhanced angiogenesis [35–38], indi-
cating the importance of collagen in the initiation of
angiogenesis. Since HSP47 is a collagen-specific molecu-
lar chaperone, it is speculated that antisense ODNs indi-
rectly decreased the number of vessels through the re-
duction of collagen synthesis in our model. In the present
study, we showed a reduction of VEGF expression in
rats treated with antisense ODNs of HSP47, associated
with reduction of peritoneal thickness. On the other
hand, Margetts et al [39] demonstrated that treatment
with angiostatin, an inhibitor of angiogenesis, resulted in
a reduction of vessel number in a rat model of peritoneal
fibrosis without decrement of peritoneal thickness [39].
The relationship between angiogenesis and fibrosis is still
controversial. Further studies are warranted to clarify
the involvement of angiogenesis in the progression of
peritoneal fibrosis.
CONCLUSION
We demonstrated that treatment with HSP47 anti-
sense ODNs results in amelioration of in vivo progres-
sion of CG-induced peritoneal fibrosis in rats. Our results
suggest that HSP47 is an important molecule in the pro-
gression of peritoneal fibrosis. Further studies are neces-
sary to confirm the effects of HSP47 in other models of
human peritoneal sclerosis and clarify the suitability of
HSP47 as a molecular target for the treatment of patients
on CAPD with peritoneal fibrosis.
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